Epigenomics (0QXH) Stock Statistics & Valuation Metrics

Epigenomics has a market cap or net worth of EUR 953.71K. The enterprise value is EUR 11.87M.

Market Cap

EUR 953.71K

Enterprise Value

EUR 11.87M

Epigenomics has 1,096,220 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

1,096,220

Owned by Insiders

―

Owned by Institutions

―

Epigenomics’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is -33.79%.

Return on Equity (ROE)

0.00

Return on Assets (ROA)

-0.35

Return on Invested Capital (ROIC)

-33.79%

Return on Capital Employed (ROCE)

-0.34

Revenue Per Employee

113.00K

Profits Per Employee

-1.49M

Employee Count

3

Asset Turnover

0.03

Inventory Turnover

0.00

In the last 12 months, Epigenomics had revenue of 339.00K and earned -4.46M in profits. Earnings per share was -5.23.

Revenue

339.00K

Gross Profit

282.00K

Operating Income

-4.18M

Pretax Income

-4.46M

Net Income

-4.46M

EBITDA

-2.83M

Earnings Per Share (EPS)

-5.23

Beta

0.16

52-Week Price Change

4.81%

50-Day Moving Average

0.92

200-Day Moving Average

0.99

Relative Strength Index (RSI)

0.02

Average Volume (3m)

5

Epigenomics upcoming earnings date is ―, TBA (Confirmed).

Last Earnings Date

Aug 12, 2026

Next Earnings Date

―

Ex-Dividend Date

―

Epigenomics as a current ratio of 5.27, with Debt / Equity ratio of 0.00%

Current Ratio

5.27

Quick Ratio

5.27

Debt to Market Cap

7.53

Net Debt to EBITDA

-3.46

Interest Coverage Ratio

0.00

In the past 12 months, Epigenomics has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

The average price target for Epigenomics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

825.00%

EPS Growth Forecast

91.38%

Smart Score

4

AI Score

―